A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion.
Burtness B, Belker M, Stoltz M, Peccerillo KM, Lamb LA, Chmael SE, McKeon A, Clark MB, Winship J, Marsh JC, Pizzorno G, DeVita VT. A phase I study of the antimetabolite (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731) administered as a twice-weekly infusion. The Cancer Journal 2000, 6: 309-15. PMID: 11079170.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityRest weekNovel antimetaboliteWeekly scheduleHuman tumor xenograft modelsWeeks of therapyLife-threatening toxicityPhase I trialFrequent dosing scheduleTumor xenograft modelIndicator lesionsNoninfectious feverPersistent neutropeniaStable diseaseWeekly infusionsDose escalationDosing schedulesI trialRectal cancerAdvanced cancerInitial doseMonths durationXenograft modelPatientsPreclinical tests